Decisive business leaders recognize they can’t wait for perfect information to make critical decisions. In fact, in order to change the trajectory of a company, decisions need to be made with a base of knowledge and intuition-even amid ambiguity and in unfamiliar domains.
Our patients are no different in that they want to know with complete certainty that their Regenexx treatment will work. As a result of our commitment to research and analyzing outcome data, we have the ability to share some of our patient results through MRI imaging taken before and after their Regenexx treatments.
View a 12 year compilation of Regenexx procedure results from before and after MRI imaging of patients with osteoarthritis, low back disc herniations, ACL tears, rotator cuff tears and more common joint injuries.
As of March 2018… We have reduced our corporate partners’ orthopedic surgical costs by up to 70%* at an overall savings of over $6.1 MILLION dollars.
Click link below to use the Regenexx Live Patient Outcome Data Tool and see patient improvement ratings based on body part.
Promoting Your Employee’s Well-being through the Nation’s Leader in Regenerative Medicine
Articles From Regenexx®
- Should You Culture Expand Stem Cells for 10 Weeks?
- Should You Get a “Quickie” Bone Marrow Stem Cell Procedure?
- Lower Back Stem Cell Treatment: Top 5 Things To Know
Incorporating the Regenexx procedures into your healthcare plan is a solid business decision based on the success of our partners and the success of our patients. To date, over 95% of employees treated by Regenexx have avoided the need for further surgery. That’s a number that makes decision making as close to perfect as possible.
We look forward to having the conversation with you about how we can help.
* This data was calculated based on the gross savings realized from substituting percutaneous orthobiologic procedures for invasive, elective orthopedic surgeries within our pilot program in Des Moines, IA. Now that we have more data from more clients, we will update our cost savings on a quarterly basis using a sampling methodology, later this year we will be introducing an actuarial based process.